Skip to main content

Table 2 Odds ratios for invasive breast cancer incidence by VEGF promoter haplotype.

From: Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort

Haplotype copies

Cases/controls

OR (95% CI)

AAG

   0

188/204

1.0 (ref.)

   1

149/224

0.69 (0.51–0.92)

   2

33/56

0.62 (0.38–1.00)

   P (for trend)

 

0.008

AGG

   0

260/342

1.0 (ref.)

   1

98/133

0.97 (0.71–1.33)

   2

12/9

1.71 (0.70–4.15)

   P (for trend)

 

0.63

CGG

   0

230/327

1.0 (ref.)

   1

125/144

1.27 (0.94–1.72)

   2

15/13

1.68 (0.78–3.61)

   P (for trend)

 

0.054

CGC

   0

161/220

1.0 (ref.)

   1

170/217

1.07 (0.80–1.43)

   2

39/47

1.18 (0.73–1.90)

   P (for trend)

 

0.47

  1. Haplotypes defined by polymorphisms at -2578, -1154, and -634 of the vascular endothelial growth factor gene. Includes 370 cases of invasive breast cancer and 484 controls with complete data on all three polymorphisms. Odds ratios (ORs) adjusted for birth year, year of blood draw, and race/ethnicity. CI, confidence interval.